The development of highly effective and durable vaccines against the human malaria
parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor …

Introduction Transmission-blocking vaccines (TBV) prevent community spread of malaria by
targeting mosquito sexual stage parasites, a life-cycle bottleneck, and will be used in …

The efficient spread of malaria from infected humans to mosquitoes is a major challenge for
malaria elimination initiatives. Gametocytes are the only Plasmodium life stage infectious to …

Malaria transmission-blocking vaccines (TBVs) aim to induce antibodies that interrupt
malaria parasite development in the mosquito, thereby blocking onward transmission, and …

Malaria vaccine development has rapidly advanced in the past decade. The very first phase
3 clinical trial of the RTS, S vaccine was completed with over 15,000 African infants and …

Abstract Proteins Pfs230 and Pfs48/45 are Plasmodium falciparum transmission-blocking
(TB) vaccine candidates that form a membrane-bound protein complex on gametes. The …

An effective malaria vaccine remains a global health priority and vaccine immunogens
which prevent transmission of the parasite will have important roles in multi-component …

The Plasmodium falciparum Pf s230 and Pf s48/45 proteins are expressed during
transmission from man to mosquito and are leading candidates for a malaria transmission …

Malaria remains a major global health challenge. Appropriate use of current antimalarial
tools has reduced the disease burden, but morbidity and mortality remain unacceptably …

Monoclonal antibodies are highly specific proteins that are cloned from a single B cell and
bind to a single epitope on a pathogen. These laboratory-made molecules can serve as …